Keybank National Association OH Acquires 58,642 Shares of Pfizer Inc. $PFE

30 Apr 2026, 22:22 by Scott Moore · The Cerbat Gem

Keybank National Association OH increased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 4.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,409,179 shares of the biopharmaceutical company’s stock after buying an additional 58,642 shares during the quarter. Keybank National Association OH’s holdings in Pfizer were worth $35,089,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Triad Wealth Partners LLC boosted its stake in shares of Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 386 shares during the last quarter. ETF Store Inc. boosted its stake in shares of Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 396 shares during the last quarter. Mattern Wealth Management LLC boosted its stake in shares of Pfizer by 4.6% in the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 400 shares during the last quarter. Quest Investment Management LLC boosted its stake in shares of Pfizer by 1.3% in the third quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock worth $809,000 after buying an additional 405 shares during the last quarter. Finally, Community Bank & Trust Waco Texas boosted its stake in shares of Pfizer by 0.6% in the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock worth $1,703,000 after buying an additional 412 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Late‑stage success for ELREXFIO: Pfizer reported Phase 3 MagnetisMM‑5 topline results showing a statistically significant, clinically meaningful improvement in progression‑free survival for relapsed/refractory multiple myeloma — a clear pipeline and revenue catalyst. Pfizer’s blood cancer drug meets main goal in late-stage trial
Positive Sentiment: Vyndamax exclusivity extended until 2031: Pfizer reached settlement agreements with generic makers that delay generic entry for its $6.4bn heart‑disease drug, protecting near‑term revenue and margins for the franchise. Pfizer protects $6.4bn heart disease blockbuster from generics, for now
Neutral Sentiment: Longer‑term R&D tailwinds: the clinical trials market is forecast to expand materially through 2034, which supports the value of Pfizer’s development programs but is a broad industry tailwind rather than a company‑specific catalyst. Clinical Trials Market Analysis/Forecasts 2026-2034
Neutral Sentiment: Technical/short‑term momentum mixed: some screens flagged improving RSI, suggesting sentiment may be stabilizing after recent moves. Pfizer among 6 stocks showing bullish RSI upswing
Negative Sentiment: Near‑term earnings concerns: analysts and previews flagged an expected Q1 earnings decline, which can weigh on the stock until the earnings print. Earnings Preview: Pfizer (PFE) Q1 Earnings Expected to Decline
Negative Sentiment: Small analyst EPS cut: Erste trimmed its FY2027 EPS estimate modestly, adding to short‑term downward pressure from lower near‑term earnings expectations. Pfizer Stock Profile
Negative Sentiment: Market reaction and headlines: coverage noting the stock’s decline and settlement news likely prompted short‑term profit‑taking despite the positive pipeline/patent developments. Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study

Analyst Upgrades and Downgrades

A number of analysts have recently commented on PFE shares. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research note on Monday, March 2nd. Citigroup upped their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday. Royal Bank Of Canada reaffirmed an “underperform” rating and issued a $25.00 price target on shares of Pfizer in a report on Monday, April 20th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a report on Thursday, February 12th. Finally, Morgan Stanley upped their price target on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.74.

Check Out Our Latest Analysis on Pfizer

Pfizer Stock Performance

NYSE PFE opened at $26.27 on Thursday. The stock has a market capitalization of $149.36 billion, a price-to-earnings ratio of 19.31 and a beta of 0.43. Pfizer Inc. has a twelve month low of $21.97 and a twelve month high of $28.75. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The stock has a 50-day moving average of $27.17 and a 200 day moving average of $26.09.

Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the prior year, the firm earned $0.63 earnings per share. The business’s revenue was down 1.2% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. Pfizer’s dividend payout ratio is presently 126.47%.

Pfizer Company Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.